Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2004, p. 2185-2189, Vol. 48, No. 6
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.6.2185-2189.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
*
Department of Parasitology, Charles University, Prague, Czech Republic
Received 1 August 2003/ Returned for modification 12 November 2003/ Accepted 10 February 2004
The substituted benzimidazole omeprazole, used for the treatment of human peptic ulcer disease, inhibits the growth of the metronidazole-resistant bovine pathogen Tritrichomonas foetus in vitro (MIC at which the growth of parasite cultures is inhibited by 50%, 22 µg/ml [63 µM]). The antitrichomonad activity appears to be due to the inhibition of pyruvate decarboxylase (PDC), which is the key enzyme responsible for ethanol production and which is strongly upregulated in metronidazole-resistant trichomonads. PDC was purified to homogeneity from the cytosol of metronidazole-resistant strain. The tetrameric enzyme of 60-kDa subunits is inhibited by omeprazole (50% inhibitory concentration, 16 µg/ml). Metronidazole-susceptible T. foetus, which expresses very little PDC, is only slightly affected. Omeprazole has the same inhibitory effect on T. foetus cells grown under iron-limited conditions. Similarly to metronidazole-resistant cells, T. foetus cells grown under iron-limited conditions have nonfunctional hydrogenosomal metabolism and rely on cytosolic PDC-mediated ethanol fermentation.
ná 7, 128 44 Prague 2, Czech Republic. Phone: 420 221951811. Fax: 420 224919704. E-mail: hrdy{at}cesnet.cz.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |